Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Den finska nationella studien för att underlätta patienters tillgång till riktade läkemedel mot cancer (FINPROVE)

9 november 2026 uppdaterad av: Katriina Jalkanen, Helsinki University Central Hospital

Den finska nationella studien för att underlätta patienters tillgång till riktade läkemedel mot cancer för att fastställa effektiviteten vid behandling av avancerad cancer med en känd molekylär profil

This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.

Studieöversikt

Detaljerad beskrivning

This is a prospective non-randomized clinical trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test. The study also aims to facilitate patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing and further deeper analysis on tumor biopsies and/or liquid biopsies for biomarker analyses and resistance mechanisms. Eligible patients have an advanced cancer for which standard treatment options no longer exist and acceptable performance status and organ function. A tumour DNA, RNA or protein expression analysis is required and the results must identify at least one potentially actionable molecular variant as defined in the protocol. Molecular profiling will be utilized to determine an appropriate drug(s) from among those available in the protocol. Drug selection will be guided by a list of potential profiles, the molecular tumor board and databases of identified targets for review and approval of the recommended treatment. The protocol-specified treatment will be administered to the patient once any drug- and disease specific eligibility criteria and overall study criteria are met. Data for standard efficacy outcomes including tumor response, progression-free and overall survival as well as duration of treatment will be collected for all patients receiving treatment within the trial. In addition, treatment related toxicity will be collected according to CTCAE 5.0.

Studietyp

Interventionell

Inskrivning (Beräknad)

250

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Kuopio, Finland
        • Rekrytering
        • Kuopio University Hospital
        • Kontakt:
          • Okko Kääriäinen, MD
      • Oulu, Finland
        • Rekrytering
        • Oulu University Hospital OYS Cancer Center
        • Kontakt:
          • Sanna Iivanainen, MD. PhD.
      • Tampere, Finland
        • Rekrytering
        • Tampere University Hospital Department of Oncology
        • Kontakt:
          • Minna Tanner, MD, PhD
    • Southwest Finland
      • Turku, Southwest Finland, Finland
        • Rekrytering
        • Turku University Hospital Cancer Centre
        • Kontakt:
          • Erika Alanne, MD, PhD
    • Uusimaa
      • Helsinki, Uusimaa, Finland, 00029
        • Rekrytering
        • Helsinki University Hospital Comprehensive Cancer Center
        • Kontakt:
          • Tanja Juslin
        • Huvudutredare:
          • Katriina Jalkanen, MD, PhD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 100 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Adult (age >18 years) patient with a histologically-confirmed locally advanced or metastatic cancer who is no longer benefitting from standard anti-cancer treatment or for whom no such treatment is available or indicated.

  2. ECOG performance status 0-2

  3. Patients must have acceptable organ function as defined below. However, specific inclusion/exclusion criteria specified in the drug-specific study manual will take precedence:

    1. Absolute neutrophil count ≥ 1.5 x 109/l
    2. Hemoglobin > 8.0 mmol/l, without blood transfusion within 7 days
    3. Platelets > 75 x 109/l (not applicable for hematological patients)
    4. Total bilirubin < 1.5 x ULN
    5. AST and ALT < 3 x institutional ULN (or < 5 x ULN in patients with known hepatic metastases)
    6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 40 mL/min/1.73 m2
  4. Patients must have objectively evaluable or measurable disease (by physical or radiographic examination, according to RECIST v1.1, Lugano, IWG and ELN-AML, IMWG, RANO, GCIG, iRESIST or PCWG3.

  5. Results must be available from a tumor molecular profiling. Eligible tests may include any of the following technologies: fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), next generation sequencing (NGS) or immunohistochemistry (IHC). The test may have been performed on the primary tumor or a metastatic lesion, in a diagnostic laboratory or within the context of another commercial platform (eg Foundation Medicine), and must reveal a potentially actionable variant.

  6. Patients must have a tumor profile for which treatment with one of the approved (or under revision for approval) targeted anti-cancer drugs included in this study has potential clinical benefit based on preclinical data or clinical information.

  7. A new (obtained ≤6 months before inclusion after which no further anti-cancer therapy is allowed) fresh frozen and FFPE tumor biopsy specimen or liquid biopsy for extensive biomarker testing is mandatory before the start of treatment with a targeted agent included in the protocol.

  8. Ability to understand and the willingness to sign a written informed consent document and comply to the protocol.

  9. For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.

  10. Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Male patients should avoid impregnating a female partner. Male patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse.

Exclusion Criteria:

  1. Ongoing toxicity > grade 2, other than alopecia or > grade 1 neuropathy.

  2. Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement). Required wash out period prior to starting study treatment is at least two weeks. An exception is made for:

    1. Patients suffering from CRPC are allowed to continue androgen deprivation therapy.
    2. Medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g., megestrol acetate, bisphosphonates). These medications must have been started ≥ 1 week prior to enrollment on this study.
  3. Received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 14 days prior to the first dose of study intervention

  4. Patient is pregnant or nursing.

  5. Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient is clinically stable and off steroids for at least 4 weeks prior to study initiation. GMB patients apply additional exclusion criteria.

  6. Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.

  7. Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible.

  8. Patients with known left ventricular ejection fraction (LVEF) < 45% are not eligible

  9. Patients with stroke (including TIA) or acute myocardial infarction within 3 months before the first dose of study treatment are not eligible

  10. Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.

For each drug included in this protocol, specific inclusion and exclusion criteria (based on the Package Insert or manufacturers recommendations) may also apply. Drug-specific inclusion and exclusion criteria will take precedence over the inclusion/exclusion criteria listed above.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Icke-randomiserad
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Alectinib

For patients with a molecular tumor profile that can potentially be targeted by alectinib.

ALK

Andra namn:
  • Alecensa
Experimentell: Cobimetinib

For patients with a molecular tumor profile that can potentially be targeted by cobimetinib.

MEK1, MEK2

Andra namn:
  • Cotellic
Experimentell: Vismodegib

For patients with a molecular tumor profile that can potentially be targeted by vismodegib.

Hedgehog

Andra namn:
  • Erivedge
Experimentell: Trastuzumab+Pertuzumab

For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination.

HER2

Andra namn:
  • Phesgo
Experimentell: Entrectinib

For patients with a molecular tumor profile that can potentially be targeted by entrectinib.

NTRK/ ROS1, ALK

Andra namn:
  • Rozlytrek
Experimentell: Atezolizumab

For patients with a molecular tumor profile that can potentially be targeted by atezolizumab.

PD-L1

Andra namn:
  • Tecentriq
Experimentell: Vemurafenib

For patients with a molecular tumor profile that can potentially be targeted by vemurafenib.

BRAF V600

Andra namn:
  • Zelboraf
Experimentell: Regorafenib

For patients with a molecular tumor profile that can potentially be targeted by regorafenib.

KIT/BRAF, RET

Andra namn:
  • Stivarga
Experimentell: Apalutamide

For patients with a molecular tumor profile that can potentially be targeted by apalutamide.

AR

Andra namn:
  • Erleada
Experimentell: Abemaciclib

For patients with a molecular tumor profile that can potentially be targeted by abemaciclib.

CDK4/6

Andra namn:
  • Verzenio
Experimentell: Tepotinib

For patients with a molecular tumor profile that can potentially be targeted by tepotinib.

MET ex14

Andra namn:
  • Tepmetko
Experimentell: Dabrafenib

For patients with a molecular tumor profile that can potentially be targeted by dabrafenib.

RAF

Andra namn:
  • Tafinlar
Experimentell: Trametinib

For patients with a molecular tumor profile that can potentially be targeted by trametinib.

MEK1, MEK2

Andra namn:
  • Mekinist
Experimentell: Dabrafenib+Trametinib

For patients with a molecular tumor profile that can potentially be targeted by dabrafenib+trametinib combination.

RAF, MEK1, MEK2

Andra namn:
  • Tafinlanr+Mekinist
Experimentell: Pemigatinib

For patients with a molecular tumor profile that can potentially be targeted by pemigatinib.

FGFR2

Andra namn:
  • Pemazyre

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Disease control rate
Tidsram: 16 weeks

Disease control rate at 16 weeks after treatment initiation (defined as patients by CR, PR, SD)

16 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Duration of treatment
Tidsram: 5 years

Time on drug

5 years
Adverse Events
Tidsram: 5 years

Treatment-related grade ≥3 and serious adverse events

5 years
Overall response
Tidsram: 5 years

Best overall response (defined as patients by CR, PR, SD)

5 years
PFS
Tidsram: 5 years

Progression free survival

5 years
OS
Tidsram: 5 years

Overall survival

5 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Katriina Jalkanen, MD, PhD, Helsinki University Hospital Comprehensive Cancer Centre

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

10 december 2021

Primärt slutförande (Beräknad)

25 november 2031

Avslutad studie (Beräknad)

25 november 2032

Studieregistreringsdatum

Först inskickad

3 december 2021

Först inskickad som uppfyllde QC-kriterierna

3 december 2021

Första postat (Faktisk)

16 december 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

10 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Investigators plan to share the clinical study report.

Tidsram för IPD-delning

2026-2027

Kriterier för IPD Sharing Access

Will be made available through European regulatory CTIS programme.

IPD-delning som stöder informationstyp

  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera